Long Term Survival of PLHIV. DR Chow TS Infectious Disease Unit Hospital Pulau Pinang
|
|
- Stuart Carr
- 5 years ago
- Views:
Transcription
1 Long Term Survival of PLHIV DR Chow TS Infectious Disease Unit Hospital Pulau Pinang
2 Natural Progression of HIV
3 Combination ART
4 Combination of antiretroviral drugs of at least 3 or more as a regime By using 2 NRTI plus 1 NNRTI boosted PI. INSTI cart
5 Goal of Antiretroviral Therapy Improve quality of life Reduce HIV-related morbidity and mortality Restore and/or preserve immunologic function Maximally and durably suppress HIV viral load Prevent HIV transmission
6 Relative Levels Therapeutic Goal of HAART FIRST LINE CD4+ FOREVER T-cells Plasma HIV Viremia? Long term durability Viral Load: Limit of detection Months Years After HIV Infection Acute HIV infection Symptom
7
8 MALAYSIA CONSENSUS GUIDELINES ARVT IN ADULT 2016
9 NRTI Abacavir (ABC) Didanosine (ddi) Emtricitabine (FTC) Lamivudine (3TC) Stavudine (d4t) Tenofovir (TDF) Zidovudine (AZT, ZDV) NNRTI Delavirdine (DLV) Efavirenz (EFV) Nevirapine (NVP) Etravirine (ETR) Rilpivirine (RPV) Current ARV Medications PI Atazanavir (ATV) Darunavir (DRV) Fosamprenavir (FPV) Indinavir (IDV) Lopinavir (LPV) Nelfinavir (NFV) Ritonavir (RTV) Saquinavir (SQV) Tipranavir (TPV) Integrase Strand Transfer Inhibitor (INSTI) Raltegravir (RAL) Dolutegravir (DTG) Fusion Inhibitor Enfuvirtide (ENF, T-20) CCR5 Antagonist Maraviroc (MVC) 9
10 HOW LONG CAN PLHIV SURVIVED WITH ART?
11
12 Expected age of death of 35 year old men with CD4 < (68-73) (74-82) > (72-81) 95% CI (compare to General pop in UK 78 )
13
14
15 PLHIV on LONG TERM ART More long term morbidity due to ART AE > OI of AIDS Need to deal with more NCD as aging is common among PLHIV Choosing the right ART is important: Potent ART Toxicity (acute and long term) Simplicity (fixed dose combination)
16 Adverse effects of ART
17 Choosing a lifelong ART Considering comorbidities ART accelerates comorbidities e.g. CVD, CKD, fractures Comorbidities increase complexity of care reduce ART adherence reduce ART options increase in polypharmacy for those age 45+ Reported in only ~25% of initial ART trials, and underassessed in routine care, so under-appreciated Gifford et al, JAIDS 2000; DAD study group, AIDS 2010 ; Hasse et al, Clin Infect Dis 2011 Krentz et al. Antiviral Therapy, 2012; Lee et al, ADR Workshop, 2013; Shahmanesh et al, ADR workshop 2013
18 Concern for Older Pts with ART AE from ART and concomitant drugs common Polypharmacy is common in older HIV-infected pts Greater risk of drug drug interactions Bone, kidney, metabolic, cardiovascular, and liver should be monitored closely DHHS Guidelines. July Slide credit: clinicaloptions.com
19 Participants (%) People (n) ATHENA and Swiss HIV Cohort Studies: Polypharmacy Among HIV-Infected Pts on ART Swiss HIV Cohort Study (N = 8444) [2] Prospective Observational Study n = 5761 n = 2233 n = 450 < 50 Yrs Yrs 65 Yrs No comedication 1 comedication 2 comedication 3 comedications 4+ comedications 16,000 14,000 12,000 10, ATHENA Modeling Study [1] 3+ comedications 2 comedications 1 comedication No comedication % of pts yrs of age and 14.2% of pts 65 yrs of age received 4 meds other than ART Predicts that 20% of pts will be receiving 3 meds other than ART in Smit M, et al. Lancet Infect Dis. 2015;15: Hasse B, et al. Clin Infect Dis. 2011:53; Slide credit: clinicaloptions.com
20 Elderly : ART and comorbidities Scenario CKD (egfr < 60 ml/min) Consider Avoiding TDF, especially in RTVcontaining regimens Osteoporosis CVD risk Hyperlipidemia TDF ABC PI/RTV
21 Key Interactions: Boosted PI- or NNRTI-Containing ART Regimens Regimen Key Drug Drug Interactions Boosted PI ATV/RTV LPV/RTV DRV/RTV Avoid lovastatin, simvastatin (lipid-lowering agents), salmeterol (asthma/copd medication) Use caution with other lipid-lowering agents (eg, atorvastatin, rosuvastatin, pravastatin) Use caution with/avoid specific antiarrhythmics (eg, amiodarone) Avoid PPIs (eg, omeprazole) with ATV RPV Avoid PPIs (eg, omeprazole, pantoprazole), dexamethasone EFV No notable comedications to avoid for EFV; consider alternative corticosteroid to dexamethasone References in slidenotes. Slide credit: clinicaloptions.com
22 Key Interactions: INSTI-Containing ART Regimens Consider to assist with identifying potential interactions for all regimens Regimen All INSTIs [1-5] DTG RAL Key Drug Drug Interaction Considerations Use caution with/avoid simultaneous polyvalent cation-containing antacids Eg MMT. Alluminium. Ca Dose adjust metformin (diabetes medication) need to reduce dose of metformin No notable comedications to avoid for RAL aside from aluminum/magnesium antacids References in slidenotes. Slide credit: clinicaloptions.com
23 An Aging Population of PLHIV
24 Probability of Survival Decreased Life Expectancy in Older HIV-Positive Adults in Modern ART Era Population-based cohort study of survival in HIV-infected pts (n = 2440) and uninfected controls matched by age and sex (n = 14,588) in Denmark HIV-Negative Controls HIV-Positive Pts Age (Yrs) Legarth RA, et al. J Acquir Immune Defic Syndr. 2016;71: Slide credit: clinicaloptions.com
25 Proportion of HIV-Positive Pts ATHENA: Older Pts Becoming More Prevalent in the HIV-Infected Population Observational cohort of 10,278 HIV-infected pts in the Netherlands Modeling study projections: Proportion of HIV-positive pts 50 yrs of age to increase from 28% in 2010 to 73% in 2030 Median age of HIV-positive pts on combination ART to increase from 43.9 yrs in 2010 to 56.6 yrs in > 70 yrs of age yrs of age yrs of age yrs of age yrs of age < 30 yrs of age Smit M, et al. Lancet Infect Dis. 2015;15: Slide credit: clinicaloptions.com
26 Comorbidities more common in HIV % HIV-negative (n=452) HIV-positive (n=489) Comorbidities n Significantly more cardiovascular disease, liver disease, renal failure and cancer in HIV+ Schouten et al. Clin Infect Dis 2014
27 Pts (%) AGEhIV: Older HIV-Infected Pts at Increased Risk for Multiple Comorbidities Cross-sectional analysis of comorbidity prevalence in prospective cohort study of HIVinfected pts (n = 540) vs controls (n = 524) 45 yrs of age P <.001 HIV-uninfected pts HIV-infected pts P =.018 P =.008 P =.044 Schouten J. Clin Infect Dis. 2014;59: Slide credit: clinicaloptions.com
28 Factors Related to Non-AIDS Comorbidities in HIV-Infected Pts Factors AGING Chronic HIV infection ART toxicity HCV and other coinfections Genetics Obesity, exercise, diet, smoking Stress Depression Conditions Inflammation and fibrosis Dyslipidemia Insulin resistance Decreased physical functioning End Organ Disease Cardiovascular Renal Metabolic Functional Neuropsychiatric Warriner AH, et al. Infect Dis Clin North Am. 2014;28: Slide credit: clinicaloptions.com
29 Is HIV immune activation? OR immune destruction?
30 HIV and Inflammation HIV infection induces a persistent inflammatory response, resulting in pathogenic responses and endorgan disease Elevated levels of inflammatory markers, including IL- 6, associated with increased risk of non-aids comorbidities and mortality in HIV-infected pts [1-4] ART partially reduces some inflammatory biomarker levels; however, they may still remain elevated vs healthy HIV-uninfected individuals [3,4] 1. Tenorio AR, et al. J Infect Dis. 2014;210: So-Armah KA, et al. J Acquir Immune Defic Syndr. 2016;72: Nixon DE, et al. Curr Opin HIV AIDS. 2010;5: Neuhaus J, et al. J Infect Dis. 2010;201: Slide credit: clinicaloptions.com
31 Inflammation Associated With Disease Mortality [1-4] in Treated HIV Infection Cardiovascular disease [5] Cancer [6] Venous thromboembolism [7] Type 2 diabetes [8] Radiographic emphysema [9] Renal disease [10] Bacterial pneumonia [11] Cognitive dysfunction [11] Depression [13] Functional impairment/frailty [14] References in slidenotes. Slide credit: clinicaloptions.com
32 Case discussion year old man Presented with Pneumocystis pneumonia CD4 20, VL > 2 million cp/ml Underlying HTN, DM (creatinine 80, clearance 62 ml/min) commences ART with TDF/FTC/EFV 2 weeks later 2009 switched to TDF-FTC + LPV/r because of ongoing CNS side effects of EFV (VL <20) CD4 > 350, plasma HIV RNA always <20 copies/ml Dev chronic diarrhoea but not too bad (no LOW) 2017 (now 63 year old man) smoker, BMI 30 TG 14.3, Total Choleterol 6.4, HDL 0.8 FBS 9.8 BP 160/90 Creatinine umol/ml (creatinine clearance = 62 declined to 45ml/min )
33 Current Medication: ART: TDF/FTC/LPV/r HTN : perindropril 4 mg OD, amlodipine 10 mg OD Hyperlipidemia: Atorvastatin 60 mg ON and Lipanthyl penta 145 mg ON DM: Metformin 1 gm BD, Gliclazide 80 mg BD Total medicine = 8 types
34 What is the issue here? 1. Aging 2. CKD 3. Hyperlipidemia (Cholesterol and TG) 4. DM uncontrolled 5. HTN uncontrolled 6. Increased ASCVD risk 7. Bone health
35 HIV and CVD, HTN
36 CVD Mortality Higher in HIV-Infected (Even With Virologic Suppression) Analysis of CVD-related mortality in HIV-infected pts in New York City HIV Surveillance Registry (N = 145,845) 71% male; median age: 49 yrs From , CVD mortality increased in HIV-infected pts (from 6% to 15%) while decreasing in the general population Age-adjusted rate of CVD mortality markedly decreased for HIV-infected pts with virologic suppression HIV-1 RNA 400 copies/ml, 8.02/1000 PY HIV-1 RNA < 400 copies/ml, 3.99/1000 PY General population, 3.22/1000 PY Hanna DB, et al. Clin Infect Dis. 2016;63: Slide credit: clinicaloptions.com
37 CVD Risk Factors in the HIV Population Gender Age Family History HIV Infection Orange = Modifiable Green = Non-modifiable Purple = HIV-associated hs-crp? ARV Lipids* CVD Risk *Metabolic syndrome ARV: antiretroviral therapy; hs-crp: high-sensitivity C-reactive protein Adapted from Carr A. Clinical Care Options HIV. Available at: Insulin Resistance Inactivity, Diet Hyperglycemia* Diabetes Abdominal Obesity* Cigarette Smoking - Hypertension*
38 Hypertension is more prevalent Analysis of HTN in HIV-infected pts in UNC CFAR HIV Clinical Cohort, (N = 3141) [1] Hypertension incidence 1996: 1.68 cases/100 PY 2013: 5.35 cases/100 PY Key risk factors Age Obesity Diabetes Renal insufficiency Nadir CD4+ cell count < 500 cells/mm 3 1. Okeke NL, et al. Clin Infect Dis. 2016;63: van Zoest RA, et al. Clin Infect Dis. 2016;63: HIV-Infected Pts Analysis of HTN in HIV-infected (n = 527) and HIV-uninfected (n = 517) persons in AGEhIV cohort [2] HTN rate higher among HIV-infected vs HIV-uninfected persons 48% vs 36%; aor: 1.65; 95% CI: Slide credit: clinicaloptions.com
39 LIPID: To Treat or Not To Treat ASCVD Risk Estimator Consider High Intensity Statin and Aspirin tools.acc.org/ascvd-risk-estimator/. Slide credit: clinicaloptions.com
40 Hyperlipidemia
41
42 Approach to HIV+ on ART with high Observation ASCVD risk Recommendations Virologic suppression can reduce CVD risk HIV-infected pts have increased CVD risk ART can increase dyslipidemia Numerous challenges exist in treating HIV infection in aging pts Controlling other metabolic comorbidities (many of which occur more frequently in HIV-infected pts) can also reduce the risk of CVD HTN, T2DM, CKD, lipid abnormalities Lifestyle modification (exercise, diet, smoking cessation) may also reduce risk Manage lipids with statin therapy; consider potential DDIs with boosted PI- or COBI-containing regimens Assess comorbidities and potential interplay with ART regimens Bone, lipid, or cardiovascular abnormalities can be exacerbated by specific therapeutics Consider polypharmacy and potential DDIs Slide credit: clinicaloptions.com
43 Approach to Lipid-Lowering (Statin) Therapy HIV-infected patients are at increased risk for ASCVD [1,2] ART can cause increases in triglycerides and total, VLDL, LDL, and HDL cholesterol Prescribing statins can be challenging due to DDIs, insulin resistance, adverse events, and increased pill burden [1] Aspect of Statin Therapy Recommendation Goal of therapy CVD risk reduction [1] Screening A fasting lipid panel should be obtained in all newly diagnosed HIV-infected pts [1,3] Lipid screening annually [3] Statin therapy is first-line therapy for elevated LDL-C and non-hdl-c [1] Treatment Moderate- or high-intensity statin therapy should be considered [1] Lifestyle therapy is the recommended first step [4] Other Patient-provider discussion is central to decisions on drug treatment [1] References in slidenotes. Slide credit: clinicaloptions.com
44 Suggested Statins with ART PI- or COBI-Containing Regimens High-Intensity Statin Moderate-Intensity Statin Low-Intensity Statin Atorvastatin 20 mg Atorvastatin 10 mg Pravastatin mg Rosuvastatin mg Rosuvastatin 5 mg Fluvastatin mg Pravastatin mg* Simvastatin and lovastatin are contraindicated for pts receiving a PI, COBI, and/or RTV *With darunavir, reduce pravastatin to mg NNRTI-, RAL-, or DTG-Containing Regimens High-Intensity Statin Moderate-Intensity Statin Low-Intensity Statin Atorvastatin mg Atorvastatin mg Pravastatin mg Rosuvastatin 20 mg Rosuvastatin 10 mg Fluvastatin mg Pravastatin mg Lovastatin 40 mg Simvastatin mg Lovastatin 20 mg Simvastatin 10 mg Dubé MP. Lipid management p Slide credit: clinicaloptions.com
45
46 # HIV and CKD
47 #
48 Management of HIV with CKD
49 Monitoring Kidney Disease For egfr: Use CKD-EPI formula based on serum creatinine, gender, age and ethnicity because egfr quantification is validated > 60 ml/ min. The abbreviated modification of diet in renal disease (amdrd) or the Cockcroft-Gault (CG) equation may be used as an alternative; see
50
51 Monitoring RP BP, RP, BP, RP, U FEME, UPCR 4 weeks 3months 3 months 3 months 3 months 6 months 6 months HAART If creatinine clearance <50 ml/min Urine RBC ++ US KUB Refer Nephrologist
52 home/guidelines/ckd-evaluationmanagement) Definition of CKD egfr < 60 ml/min for > 3 months. If not known to have CKD, confirm the egfr within 2 weeks. Use of DTG, COBI and RTV boosted PIs is associated with an increase in serum creatinine/reduction of egfr due to inhibition of proximal tubular creatinine transporters without impairing actual glomerular filtration: consider new set point after 1-2 months
53 ARV- TDF associated Nephrotoxicity TDF - Proximal tubulopathy with any combination of: 1. Proteinuria: urine dipstick 1, or confirmed increase in UP/C > 30 mg/mmol 2. Progressive decline in egfr and egfr < 90 ml/min 3. Phosphaturia: confirmed hypophosphataemia secondary to increased urine phosphate leak Assessment: Tests for proximal renal tubulopathy/renal Fanconi syndrome Consider renal bone disease if hypophosphataemia of renal origin: measure 25(OH) vitamin D, PTH, DXA scan Consider stopping TDF if: Progressive decline in egfr and no other cause Confirmed hypophosphataemia of renal origin and no other cause Osteopenia/osteoporosis in the presence of increased urine phosphate leak
54 ARV- PI associated Nephrotoxicity ATV / IDV (DRV) induced nephrolithiasis Crystalluria Hematuria Leucocytes in urine Loin pain AKI Assessment: Urinalysis for crystalluria/stone analysis Exclude other cause for nephrolithiasis Renal tract imaging including CT scan Consider stopping IDV/ATV if: Confirmed renal stones Recurrent loin pain +/- haematuria
55 ARV- PI associated Nephrotoxicity IDV/ATV induced interstitial nephritis Progressive decline in egfr Tubular proteinuria Hematuria Leucocyte casts in urine Assessment: Renal ultrasound Refer to nephrologist Consider stopping IDV/ATV if: Progressive decline in egfr and no other cause
56 Dosage of ARV adjustment for CKD No dose adjustment NRTI Abacavir, zidovudine All NNRTI All PI/r All INSTI Dose adjustment needed NRTI ARV > <10 3TC FTC TDF 300 mg OD No single agent 300 mg OD 150 mg OD 300 mg every 48 H 100 mg OD #300 mg every 72 H 50 mg OD #300 mg weekly # not recommended but if no alternative Tenvir EM One tab OD One tab every 48 H Use single agent
57 HIV on ARV with Frailty and Bone health
58 The Concept of Frailty Multisystem clinical syndrome that reflects biological rather than chronological age; regarded as an end-stage state [1] Associated with loss of functional homeostasis, inability to recover fully after stressors, and morbidity and excess mortality [1] Frailty Characteristic Shrinking Muscle weakness Poor endurance/exhaustion Fried Frailty Phenotype [2] Clinical Criteria* Unintentional weight loss (> 10 lbs) in prior year, sarcopenia Poor grip strength (lowest quintile by sex, BMI) Self-reported exhaustion Slowness Other tools: FRAIL Scale, Study Walking of Osteoporotic time per 15 ft Fractures (slowest quintile (SOF) by index, sex, height) Clinical Frailty Scale [3-5] Low activity Low kcal/week expenditure (lowest quintile by sex) *Frailty defined as presence of 3 criteria; prefrailty as presence of 1-2 criteria. References in slidenotes. Slide credit: clinicaloptions.com
59
60 Incidence (%) Frailty Risk Factors in Aging HIV-Positive HR: 3.9 P <.001 Risk Factors (OR: Frail vs Nonfrail) HR: 3.9 P =.002 HR: 3.7 P =.004 HR: 3.6 P =.001 Frail (n = 33) Prefrail (n = 185) Nonfrail (n = 141) HR: 3.3 P = HR: 5.1 P =.007 HR: 3.8 P =.067 HR: 3.5 P = Diabetes Neurologic Disease Psychiatric Disease CVD Unhealthy Weight Arthritis Osteoporosis Viral Hepatitis Erlandson KM, et al. IAS Abstract TUPE124. Slide credit: clinicaloptions.com
61 ART Considerations for Pts With Bone Complications TDF Consider avoiding TDF: associated with greater decrease in BMD along with renal tubulopathy, urine phosphate wasting, and osteomalacia Consider ABC/3TC TDF/FTC + INSTI OR PI/r: Significantly greater BMD loss with PI/r vs RAL-based regimens (when used with FTC/TDF) [2] DTG/ABC/3TC associated with less bone turnover than EFV/TDF/FTC [3] 1. DHHS Guidelines. July Brown TT, et al. J Infect Dis. 2015;212: Tebas P, et al. AIDS. 2015;29: Slide credit: clinicaloptions.com
62 Fracture Prevalence/ 100 Persons Fracture Prevalence/ 100 Persons Fracture Prevalence Increased in Older HIV-Infected Pts Meta-analysis: HIV-positive pts had 6.4-fold increased risk of low BMD and 3.7-fold increased risk of osteoporosis [1] (8525 HIV-infected pts compared with 2,208,792 uninfected pts in Partners HealthCare System, [2]) HIV Non- HIV Women P =.002 (overall comparison) Age (Yrs) Men P <.0001 (overall comparison) Age (Yrs) HIV Non- HIV Brown TT, et al. AIDS. 2006;20: Triant V, et al. J Clin Endocrinol Metab. 2008;93: Slide credit: clinicaloptions.com
63 Fracture risk assessment McComsey et al, Clin Infect Dis 2010;
64 Bone disease screening and diagnosis in HIV Classic risk factors: older age, female gender, hypogonadism, family history of hip fracture, low BMI ( 19 kg/m2), vitamin D deficiency, Esp TDF smoking, physical inactivity, history of low trauma fracture, alcohol excess (> 3 units/day), steroid exposure (minimum prednisone 5 mg/qd or equivalent for > 3 months) If T-score normal, repeat after 3-5 years in risk groups 1, 2 and 5; no need for rescreening with DXA in risk groups 3 and 4 unless risk factors change and only rescreen group 6 if steroid use ongoing.
65 Change (%) Huang et al, AIDS 2009 Low BMD therapy: prevention / drug therapy General Reduce risk of falls Bisphosphonate therapy Exercise weight-bearing muscle strength balance training Vitamin D and calcium replacement / supplementation Avoid TDF /PI Bisphosphonate treatment of: alendronate 70 mg once weekly po; risedronate 35 mg once weekly po; ibandronate 150 mg po or 3 mg iv every 3 months; zoledronic acid 5 mg iv once yearly.
66 Recommendations for Evaluation of Brown TT, et al. Clin Infect Dis. 2015;60: Bone Disease in HIV HIV-Infected Population Assessment Monitoring Men yrs of age Premenopausal women 40 yrs of age Men 50 yrs of age Postmenopausal women Pts with fragility fracture history, receiving chronic glucocorticoids, or at high risk of falls Assess risk of fragility fracture using FRAX Assess BMD using DXA For pts with FRAX score 10%, monitor FRAX in 2-3 yrs For pts with FRAX score > 10%, perform DXA For pts with advanced osteopenia, monitor DXA in 1-2 yrs For pts with mild or moderate osteopenia, monitor DXA in 5 yrs For pts started on bisphosphonates (significantly reduced BMD or fracture history), repeat DXA in 2 yrs Slide credit: clinicaloptions.com
67 ART and frailty Observation Frailty is more prevalent among HIV-infected vs HIVuninfected individuals Fracture prevalence and low BMD common among pts with HIV Some ART regimens have larger impact on BMD loss than others Assess pts for frailty; Recommendations consider Fried Frailty Phenotype or other available tests Assess pts for BMD loss or risk of bone disease depending on risk factors For pts at risk for or with BMD loss or bone disease, consider ART modifications Backbone: consider ABC/3TC > TDF/FTC Greater BMD loss observed with PI-based regimens vs INSTI based regimens
68 HIV on ARV and Liver dysfunction
69 Abnormal LFT in HIV Co infection with HCV and HBV Opportunistic infections Non-viral causes of abnormal LFT: common etiologies Drug-induced liver injury (DILI) include herbs, supplements and ART Alcohol Fatty liver in HIV - multifactorial, potentially reversible etiology for chronic liver disease Autoimmune hepatitis Acharya C, et al. Clin Liver Dis 2015 Feb;19(1):1-22. Molina PE, et al. Curr HIV Res. 2014;12(4):
70 1. DILI-Liver toxicity of antiretroviral drugs Drug Class Drug Severe ALT Elevation (%)* NRTI Lamivudine Tenofovir 16 4 Zidovudine Emtricitabine Abacavir 19 6 Didanosine 20 6 Stavudine NNRTI Rilpivirine 22 <1-2 Etravirine Delavirdine Efavirenz Nevirapine PI Nelfinavir Indinavir Darunavir/ritonavir Fosamprenavir/ritonavir Ritonavir Atazanavir/ritonavir Tipranavir/ritonavir Lopinavir/ritonavir CCR5 blocker Maraviroc Integrase inhibitor Raltegravir 36 4 Fusion inhibitor Enfuvirtide DILI, drug-induced liver injury; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor; CCR5, chemokine receptor type 5; ALT, alanine aminotransferase; ULN, upper limit of normal. * Note. No data provided in package insert for Saquinavir. Jones M, Núñez M. Semin Liver Dis 2012 May;32(2):
71 GRADING of LIVER Dysfucntion Jones M, Nu n ez M. Semin Liver Dis 2012 May;32(2):
72
73
74 Cancer and HIV
75
76 Cancer screen in HIV
77 Others NCD HAND
78 Back to the Case year old man Presented with Pneumocystis pneumonia CD4 20, VL > 2 million cp/ml Underlying HTN, DM (creatinine 80, clearance 62 ml/min) commences ART with TDF/FTC/EFV 2 weeks later 2009 switched to TDF-FTC + LPV/r because of ongoing CNS side effects of EFV (VL <20) CD4 > 350, plasma HIV RNA always <20 copies/ml Dev chronic diarrhoea but not too bad (no LOW) 2017 (now 63 year old man) smoker, BMI 30 TG 14.3, Total Choleterol 6.4, HDL 0.8 FBS 9.8 BP 160/90 Creatinine umol/ml (creatinine clearance = 62 declined to 45ml/min )
79 What is the issue here? Aging CKD Hyperlipidemia (Cholesterol and TG) DM uncontrolled HTN uncontrolled Increased ASCVD risk Bone health Frailty avoid TDF Avoid TDF (adjust dose) High ASCVD risk > 50 % Avoid ABC Hyperglycemia and hyperlidemia due to Kaletra Optimised anti HTN and antilipid Anti platelet therapy
80 Modify ARVT First line/ Never failed therapy (Intolerant to NNRTI) Cessation of smoking, start aspirin 75 mg OD Atorvastatin 60 mg OD 80 mg OD ( BUT once stopped PI/r, TG and Chol level will reduced and blood sugar as well) Continue fenofibrate Add ezetimibe 10 mg OD? Switched PI/r? NNRTI? Which one?
81 NEAT 022: Switch From Boosted PI to DTG in Suppressed Pts With High CV Risk PI-based regimens associated with increased risk of dyslipidemia [1] NEAT 022: international, randomized, open-label phase IV study [2,3] Primary endpoints at Wk 48: proportion with HIV RNA < 50 c/ml (ITT), change in total plasma cholesterol Wk 48 Wk 96 Pts with stable HIV-1 RNA < 50 c/ml on PI/RTV + 2 NRTIs, high CV risk,* no resistance mutations, no VF (N = 415) Immediate switch to DTG + 2 NRTIs (n = 205) Continue PI/RTV + 2 NRTIs (n = 210) Deferred switch to DTG + 2 NRTIs *> 50 yrs of age and/or Framingham risk score > 10% at 10 yrs. NRTIs to remain the same throughout study. 1. Ofotokun I, et al. Clin Infect Dis. 2015;60: Gatell JM et al. IAS Abstract TUAB ClinicalTrials.gov. NCT Slide credit: clinicaloptions.com
82 ITT Population (%) Mean Change From BL to Wk 48 (%) NEAT 022: Switch From Boosted PI to DTG in Suppressed Pts With High CV Risk Switching to DTG noninferior to continuing boosted PI through Wk Virologic Success Treatment difference: -2.1% (95% CI: -6.6% to 2.4%) Virologic Nonresponse No Virologic Data No emergent resistance in pts with VF No significant differences in grade 3/4 AEs, serious AEs, AE-related d/c DTG PI/RTV 10 Switching to DTG associated with improved lipid profile vs continuing boosted PI through Wk DTG PI/RTV 0.7 P < P < P < P <.001 P =.286 P <.001 TC Non-HDL-C TG LDL-C HDL-C TC/HDL Ratio Gatell JM et al. IAS Abstract TUAB0102. Slide credit: clinicaloptions.com
83
84 Case discussion High CVD risk with hyperlipidemia secondary to PI/r Renal function declining (creatinine clearance < 50 ml/min) Issue of Aging, bone health and frailty Avoid ABC, and TDF, avoid PI /r Dolutegravir 50 mg OD + 3TC 150 mg OD
85 Summary With ART, life expectancy of PLHIV has increased Appropriate Mx of co morbidities : CV, Renal, Liver, Bone, CNS and Cancer screening need to be done as part of the Mx for HIV Multidisciplinary approach Monitor not only CD4 and HIV VL Metabolic screen and CVD risk modification Renal function and liver function Cancer screen Bone health and Fried frailty score Neurocognitive assessment IHDS and MOCA ART prolonged survival of PLHIV, maintain quality of health is ultimate aim
86
HIV Update. On The Cutting Edge A Chronic Disease. Rhett M Shirley, MD
HIV Update On The Cutting Edge A Chronic Disease Rhett M Shirley, MD CDC Mid-point life expectancy estimates at age 20 years in three calendar periods, overall and by sociodemographic characteristics,
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More informationHIV and the Aging Patient: Managing Co-morbidities. Heather Free, PharmD, AAHIVP
HIV and the Aging Patient: Managing Co-morbidities Heather Free, PharmD, AAHIVP Objectives Review HIV/AIDS statistics within the United States Define HIV and Aging and life expectancy List treatment issues
More informationSwitching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches
Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches Harry W. Lampiris, MD Chief, Infectious Disease Section, San Francisco VA Medical Center Professor
More informationThe use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines
The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines I. Boucoiran, T. Lee, K. Tulloch, L. Sauve, L. Samson, J. Brophy, M. Boucher and D. Money For and
More informationThe ART of Managing Drug-Drug Interactions in Patients with HIV
The ART of Managing Drug-Drug Interactions in Patients with HIV Bradley L. Smith, Pharm.D. smith.bradley1@mayo.edu Pharmacy Grand Rounds December 19, 2017 2017 MFMER slide-1 Presentation Objectives Describe
More informationPharmacological considerations on the use of ARVs in pregnancy
Pharmacological considerations on the use of ARVs in pregnancy 11 th Residential Course on Clinical Pharmacology of Antiretrovirals Torino, 20-22 January 2016 Prof. David Burger, PharmD, PhD david.burger@radboudumc.nl
More informationContinuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
More informationSimplifying HIV Treatment Now and in the Future
Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line
More informationSusan L. Koletar, MD
HIV/AIDS Susan L. Koletar, MD Division Director, Infectious Diseases Professor of Internal Medicine Department of Internal Medicine The Ohio State University Wexner Medical Center HIV through the Decades
More informationDisclosures. Update on HIV Drug Therapy: A Case based Discussion. Case # 1: Dr. Grant has received grant support from BMS, Gilead, Janssen, and Viiv
Disclosures Update on HIV Drug Therapy: A Case based Discussion Dr. Grant has received grant support from BMS, Gilead, Janssen, and Viiv Philip Grant Assistant Professor Division of Infectious Diseases
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationCOMPETING INTEREST OF FINANCIAL VALUE
BHIVA AUTUMN CONFERENCE 2012 Including CHIVA Parallel Sessions Dr Ian Williams University College London Medical School COMPETING INTEREST OF FINANCIAL VALUE > 1,000: Speaker Name Statement Ian Williams
More informationReal Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort
Real Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort Yagci-Caglayik D 1, Gokengin D 2, Inan A 3, Ozkan-Ozdemir H 4, Inan D 5, Akbulut A 6, Korten V 1,
More information2/10/2015. Switching from old regimens. HIV treatment revision: As simple as old versus new? What is an old regimen? What is an old regimen?
Switching from old regimens David Nolan Department of Immunology, Royal Perth Hospital, Western Australia Institute for Immunology and Infectious Diseases, Murdoch University, Western Australia What is
More informationART and Prevention: What do we know?
ART and Prevention: What do we know? Biomedical Issues Trip Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Cornell Medical College New York City ART for Prevention:
More informationWhen to Start ART. Reduction in HIV transmission. ? Reduction in HIV-associated inflammation and associated complications» i.e. CV disease, neuro, etc
When to Start ART Exact CD4 count at which to initiate therapy not known, but evidence points to starting at higher counts Current recommendation: ART for all patients with CD4 count of
More informationSusan L. Koletar, MD
HIV/AIDS Susan L. Koletar, MD Division Director, Infectious Diseases Professor of Internal Medicine Department of Internal Medicine The Ohio State University Wexner Medical Center HIV through the Decades
More informationHIV - Therapy Principles
HIV - Therapy Principles Manuel Battegay and Christine Katlama Basel, Switzerland and Paris, France Disclosure MB has received honoraria for advisory board participation from Gilead, MSD, Pfizer, ViiV
More informationUpdate on Antiretroviral Treatment for HIV Infection 2008
Update on Antiretroviral Treatment for HIV Infection 2008 Janet Gilmour MD FRCP(C) Clinical Associate Professor of Medicine University of Calgary November 2008 Disclosure and Acknowledgements Disclosure:
More informationSelecting an Initial Antiretroviral Therapy (ART) Regimen
Selecting an Initial Antiretroviral Therapy (ART) Regimen An HIV Diagnosis is a Call to Action In support of the NYSDOH AIDS Institute s January 2018 call to action for patients newly diagnosed with HIV,
More informationHIV in in Women Women
HIV in Women Susan L. Koletar, MD The Ohio State University How Many of These Women Have HIV? Answer: I don t really know Google Search: Photos of Groups of Women Pub Med Search: HIV and Women 22,732
More informationAntiretroviral Dosing in Renal Impairment
Protease Inhibitors (PIs) Atazanavir Reyataz hard capsules 300 mg once daily taken with ritonavir 100 mg once daily No dosage adjustment is needed for atazanavir in renal impairment Atazanavir use in haemodialysis
More informationTDF containing ART: Efficacy and Safety. Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia
TDF containing ART: Efficacy and Safety Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia 1 Indications Treatment of HIV-1 in combination with other antiretroviral
More informationPediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV. Ernesto Parra, M.D., M.P.H.
Pediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV Ernesto Parra, M.D., M.P.H. Adjunct Associate Professor UTHSCSA Department of Pediatrics and Family and Community
More informationStarting and Switching ART: 2016
Starting and Switching ART: 2016 Luke Jerram Rajesh T. Gandhi, M.D. Massachusetts General Hospital Harvard Medical School Disclosures: grant support from EBSCO, Gilead, Merck, Viiv Thanks to Henry Sunpath,
More informationHIV for the Non-ID Pharmacist
Disclosures HIV for the Non-ID Pharmacist I have nothing to disclose at this time Carmen Faulkner-Fennell, PharmD, BCPS (AQ-ID) Clinical Pharmacy Specialist--Infectious Diseases Greenville Hospital System
More informationHIV Treatment: State of the Art 2013
HIV Treatment: State of the Art 2013 Daniel R. Kuritzkes, MD Chief, Division of Infectious Diseases Brigham and Women s Hospital Professor of Medicine Harvard Medical School Success of current ART Substantial
More informationCriteria for Oral PrEP
Oral PrEP New Drugs Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Safe Criteria for Oral PrEP Penetrates
More informationAntiretroviral Therapy: What to Start
FLOWED: 05-14-2015 Chicago, IL: May 18, 2015 Antiretroviral Therapy: What to Start Eric S. Daar, MD Professor of Medicine David Geffen School of Medicine University of California Los Angeles Los Angeles,
More informationHIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop
HIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop Parya Saberi, PharmD, MAS The Medical Management of HIV/AIDS December 2012 Objectives What are commonly used ARVs and where do they work in
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More informationHIV Treatment Update. Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London
HIV Treatment Update Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London Guidelines Nuke sparing Nukes Efavirenz placement as the gold standard ARV Role
More informationDidactic Series. Switching Regimens in the Setting of Virologic Suppression
Didactic Series Switching Regimens in the Setting of Virologic Suppression Craig Ballard, PharmD, AAHIVP UC San Diego Health Owen Clinic June 14 th, 2018 1 Learning Objectives 1) Describe DHHS guidelines
More informationD:A:D: Cumulative Exposure to DRV/r Increase MI Risk
D:A:D: Cumulative Exposure to DRV/r Increase MI Risk 20.0-15.0-10.0-5.0-4.0-3.0-2.0-1.0- Unadjusted CVD rate ratios per 5 years additional exposure: ATV/r 1.25 [1.10-1.43] and DRV/r 1.93 [1.63-2.28] Adjusted*
More informationHIV Treatment: New and Veteran Drugs Classes
HIV Treatment: New and Veteran Drugs Classes Jonathan M Schapiro, MD National Hemophilia Center Stanford University School of Medicine Rome, March 2013 Overview Many excellent antiretroviral agents are
More informationPOST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV
POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV DISCLOSURE Relevant relationships with commercial entities none Potential for conflicts of interest within this presentation none
More informationMore Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD
More Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD More Options, Some Opinions: Initial Therapies for HIV Judith S. Currier, MD University of California Los Angeles Los Angeles,
More informationSTRIBILD (aka. The Quad Pill)
NORTHWEST AIDS EDUCATION AND TRAINING CENTER STRIBILD (aka. The Quad Pill) Brian R. Wood, MD Medical Director, NW AETC ECHO Assistant Professor of Medicine, University of Washington Presentation prepared
More informationAntiretroviral Treatment Strategies: Clinical Case Presentation
Antiretroviral Treatment Strategies: Clinical Case Presentation Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan Chia-Jui, Yang M.D Disclosure No conflicts of interests.
More informationThe next generation of ART regimens
The next generation of ART regimens By Gary Maartens Presented by Dirk Hagemeister Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Current state
More informationDidactic Series. Update: 2012 HIV Treatment Guidelines. Daniel Lee, MD August 30, 2012
Didactic Series Update: 2012 HIV Treatment Guidelines Daniel Lee, MD August 30, 2012 ACCREDITATION STATEMENT: University of California, San Diego School of Medicine is accredited by the Accreditation Council
More informationStructured Treatment Interruption in HIV Positive Patients. Leah Jackson, BScPhm Pharmacy Resident HIV Rotation January 23, 2007
Structured Treatment Interruption in HIV Positive Patients Leah Jackson, BScPhm Pharmacy Resident HIV Rotation January 23, 2007 Objectives To become re-acquainted with the basics of HAART for HIV infection
More informationPrima linea: dovremmo evitare i PI nella terapia di prima linea per i loro effetti non desiderati? Giuseppina Liuzzi
6 th INFECtivology TOday Paestum 15-16 -17 maggio 2014 Prima linea: dovremmo evitare i PI nella terapia di prima linea per i loro effetti non desiderati? Giuseppina Liuzzi Istituto Nazionale per le Malattie
More informationACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals
Initial Therapy for Antiretroviral Naïve HIV Infected Patients Michelle Cespedes, MD, MS Associate Professor of Medicine Division of Infectious Disease Icahn School of Medicine at Mount Sinai Disclosures
More informationSwitching antiretroviral therapy to safer strategies based on integrase inhibitors
Switching antiretroviral therapy to safer strategies based on integrase inhibitors Dr Paddy Mallon UCD HIV Molecular Research Group UCD School of Medicine paddy.mallon@ucd.ie UCD School of Medicine & Medical
More informationHIV Diagnosis and Management 2015 Update. Faria Farhat, MD MedStar Washington Hospital Center
HIV Diagnosis and Management 2015 Update Faria Farhat, MD MedStar Washington Hospital Center Objectives Describe the epidemiology and pathogenesis of HIV infection Highlight HIV diagnosis algorithm and
More informationHIV basics. Katya Calvo Medical Director of Antimicrobial Stewardship
HIV basics Katya Calvo Medical Director of Antimicrobial Stewardship Learning Objectives 1. Review of HIV epidemiology worldwide and locally 2. Review of recommendations on whom to screen 3. Work up of
More informationSwitching antiretroviral therapy to safer strategies based on integrase inhibitors. Pedro Cahn
Switching antiretroviral therapy to safer strategies based on integrase inhibitors Pedro Cahn Disclosures Research Grants: Abbvie-Merck-Richmond-ViiV Advisory boards: Merck-Sandoz-ViiV Switching in Virologically
More informationGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationSingle Pill Combinations Versus Generics: Prescribing Practices in a New Healthcare Era
Activity Code FM285 Single Pill Combinations Versus Generics: Prescribing Practices in a New Healthcare Era Monica Gandhi MD, MPH Clinic Director, Ward 86 HIV Clinic, SFGH/UCSF Learning Objectives Upon
More informationThis graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts
1 2 This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts decreased. This period of acute infection or serocnversion
More informationCases from the Clinic(ians): Case-Based Panel Discussion
Cases from the Clinic(ians): Case-Based Panel Discussion Michael S. Saag, MD Professor of Medicine The University of Alabama at Birmingham EDITED: 03-12-14 Learning Objectives After attending this presentation,
More informationHIV infection and Primary Care. HIV Care in /30/2013. It s not the AIDS of 85. Stephen Raffanti MD MPH Vanderbilt University School of Medicine
HIV infection and Primary Care Stephen Raffanti MD MPH Vanderbilt University School of Medicine HIV Care in 2013 Chronic lifelong treatment with all the associated issues: medication tolerability medication
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More informationAntiretroviral Treatment 2014
Activity Code FM285 Antiretroviral Treatment 2014 Rajesh Gandhi, MD Masssachusetts General Hospital Disclosures: Educational grants to my institution from Janssen, Viiv, Abbott Learning Objectives Upon
More informationWhen to start, when to switch ART and monitoring of ARV side effects
When to start, when to switch ART and monitoring of ARV side effects Thanomsak Anekthananon, MD Faculty of Medicine Siriraj Hospital September 4, 2009 Recommended Websites Free e-book: HIV Medicine 2007
More informationARVs in Development: Where do they fit?
The picture can't be displayed. ARVs in Development: Where do they fit? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker
More informationCOMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL
Generic Name COMPREHENSIVE ANTIRETROVIRAL TABLE: NUCLOESIDE/TIDE REVERSE TRANSCRIPTASE INHIBITORS (N(t)RTIs) Abacavir ABC (Ziagen) Didanosine ddi (Videx EC) Emtricitabine FTC (Emtriva) Lamivudine 3TC (Epivir)
More informationSELECTING THE BEST ART FOR EACH PATIENT
SELECTING THE BEST ART FOR EACH PATIENT Corklin R Steinhart, MD, PhD Head, Global Medical Directors ViiV Healthcare CNVX/HIVP/0025/16 5th Asian Conference on Hepatitis & AIDS 第五届亚洲肝炎与艾滋病学术会议 28-29 May
More information/AIDS HIV/ HIV Overview. Nelson L. Michael, MD, PhD Division of Retrovirology Walter Reed Army Institute of Research US Military HIV Research Program
/AIDS HIV/ HIV Overview Nelson L. Michael, MD, PhD Division of Retrovirology Walter Reed Army Institute of Research US Military HIV Research Program www.hivresearch.org 1 WRAIR Tropical Medicine Course
More informationClinical support for reduced drug regimens. David A Cooper The University of New South Wales Sydney, Australia
Clinical support for reduced drug regimens David A Cooper The University of New South Wales Sydney, Australia Clinical support for reduced drug regimens First line optimisation Virological failure New
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More informationART: The New, The Old and The Ugly
ART: The New, The Old and The Ugly Our Current ARVS The Nucleoside/ Nucleotide Reverse Transcriptase Inhibitors (NRTIs/ NtRTIs) Abacavir Emtricitabine Lamivudine Stavudine Tenofovir Zidovudine The Non-Nucleoside
More information2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012
2 nd Line Treatment and Resistance Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 Overview Basics of Resistance Treatment failure Strategies to manage treatment failure Mutation Definition: A change
More informationHIV Update Allegra CPD Day Program Port Elizabeth Dr L E Nojoko
HIV Update 2014 Allegra CPD Day Program Port Elizabeth 12-02-2014 Dr L E Nojoko Global estimates for adults and children 2011 People living with HIV 34.0 million [31.4 million 35.9 million] New HIV infections
More informationSasisopin Kiertiburanakul, MD, MHS
What s Newin Antiretroviral Therapy? Sasisopin Kiertiburanakul, MD, MHS Division of Infectious Diseases Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University Rotating RCPT,
More informationNorthwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care
Northwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care www.nwaetc.org The Northwest AIDS Education and Training Center (NW AETC), located at the University
More informationHuman Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) in the Long Term Care Setting Part 2: HIV Medications
Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) in the Long Term Care Setting Part 2: HIV Medications Carrie Allen PharmD, CGP, BCPS, BCPP, CCHP Overview - Part 2: HIV
More informationDidactic Series. CROI 2014 Update. March 27, 2014
Didactic Series CROI 2014 Update Christian Ramers, MD, MPH Family Health Centers of San Diego Ciaccio Memorial Clinic Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director,
More informationApproach for the Newly Diagnosed HIV Positive Patient
Approach for the Newly Diagnosed HIV Positive Patient Jason E. Farley, PhD, MPH, ANP-BC, FAAN, AACRN Associate Professor & NP, Johns Hopkins University School of Nursing & Medicine Director, AETC Adult-Gerontology
More informationVitamin D Deficiency in HIV: A Shadow on Long-Term Management?
AIDS Rev. 2014;16:59-74 (Supplementary Data) Vitamin D Deficiency in HIV: A Shadow on Long-Term Management? Chloe Orkin, et al.: Vitamin D deficiency in HIV (Supplementary Data) Chloe Orkin 1, David A.
More informationFriday afternoon Programme
Friday afternoon Programme Pharmacology and TDM Dr Marta Boffito Consultant Physician, C&W Resistance to new anti-retrovirals Dr Steve Taylor Consultant Physician, Birmingham HIVPA Annual Conference 2008
More informationAntiretroviral Treatment (ART) of Adult HIV Infection*
Antiretroviral Treatment (ART) of Adult HIV Infection* Prepared by J Montaner for the BC- CfE Therapeutic Guidelines Committee of the British Columbia - Centre for Excellence in HIV/AIDS. *Based on M Thompson,
More informationHIV & Aging: Evolving Clinical Considerations in the New Millennium
HIV & Aging: Evolving Clinical Considerations in the New Millennium Julian Falutz, MD, FRCP (C) Director, HIV Metabolic Clinic Immunodeficiency Treatment Centre Senior Physician Division of Geriatrics
More informationOverview of HIV WRAIR- GEIS 'Operational Clinical Infectious Disease' Course
Overview of HIV WRAIR- GEIS 'Operational Clinical Infectious Disease' Course UNCLASSIFIED Acknowledgments - Dr. Christina Polyak - Dr. Julie Ake Disclaimer The views expressed in this presentation are
More informationPediatric Antiretroviral Resistance Challenges
Pediatric Antiretroviral Resistance Challenges Thanyawee Puthanakit, MD The HIVNAT, Thai Red Cross AIDS research Center The Research Institute for Health Science, Chiang Mai University Outline The burden
More informationDepartment of General Medicine, Juntendo University School of Medicine, Tokyo; and 2
Jpn. J. Infect. Dis., 69, 33 38, 2016 Original Article Raltegravir and Abacavir/Lamivudine in Japanese Treatment-Naäƒve and Treatment-Experienced Patients with HIV Infection: a 48-Week Retrospective Pilot
More informationPrevalence of Comorbidities among HIV-positive patients in Taiwan
Prevalence of Comorbidities among HIV-positive patients in Taiwan Chien-Ching Hung, MD, PhD Department of Internal Medicine National Taiwan University Hospital, Taipei, Taiwan % of participants Comorbidity
More informationThe Use of Integrase Inhibitors In Latin America: From Guidelines to the Real World Ernesto Martínez B., MD Internal Medicine, Infectious Diseases
De afbeelding kan niet worden weergegeven. The Use of Integrase Inhibitors In Latin America: From Guidelines to the Real World Ernesto Martínez B., MD Internal Medicine, Infectious Diseases DISCLOSURE
More informationCOMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING**, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL
COMPREHENSIVE ANTIRETROVIRAL TABLE: NUCLOESIDE/TIDE REVERSE TRANSCRIPTASE INHIBITORS (N(t)RTIs) Abacavir ABC (Ziagen) Didanosine ddi (Videx EC) Emtricitabine FTC (Emtriva) Lamivudine 3TC (Epivir) Stavudine
More informationAntiretroviral Drugs
Antiretroviral Drugs Dr Paddy Mallon UCD HIV Molecular Research Group Associate Dean for Research and Innovation UCD School of Medicine and Medical Science paddy.mallon@ucd.ie UCD School of Medicine &
More informationThird Agent Advantages Disadvantages. Component Tenofovir/emtricitabine (TDF/FTC) 300/200 mg (coformulated with EFV as Atripla) 1 tab once daily
Table I. Recommended and Alternative Antiretroviral Regimens (DHHS Guidelines, May 1, 2014) Recommended Regimens Nucleoside Analog Reverse Transcriptase Inhibitor (NRTI) Third Agent Advantages Disadvantages
More informationActualización y Futuro en VIH
Actualización y Futuro en VIH Dr. Santiago Moreno Servicio de Enfermedades Infecciosas Hospital U. Ramón y Cajal. Universidad de Alcalá. IRYCIS. Madrid Agenda Control of the HIV-epidemic Coinfections Antiretroviral
More informationPAEDIATRIC HIV INFECTION. Dr Ashendri Pillay Paediatric Infectious Diseases Specialist
PAEDIATRIC HIV INFECTION Dr Ashendri Pillay Paediatric Infectious Diseases Specialist Paediatric HIV Infection Epidemiology Immuno-pathogenesis Antiretroviral therapy Transmission Diagnostics Clinical
More informationDrug toxicities: Safest PIs. Michelle Moorhouse 14 Apr 2016
Drug toxicities: Safest PIs Michelle Moorhouse 14 Apr 2016 Impact of PIs on AIDS mortality CDC.gov. Epidemiology of HIV infection. Evolution of PIs http://www.clinicaloptions.com/hiv/treatment%20updates/boosted%20pis/interactive%20virtual%20presentation/slideset.aspx
More informationAntiretroviral Therapy
Antiretroviral Therapy Scott M. Hammer, M.D. 1986 1990 ZDV monorx 1990 1995 Alternative NRTI monorx Combination NRTI Rx Introduction of NNRTI s Antiretroviral resistance Pathogenetic concepts Evolution
More informationAre the current doses of ARV correct. Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine
Are the current doses of ARV correct Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine Can we lower doses of HIV meds safely? Consensus Panel in Alexandria
More information12th European AIDS Conference / EACS ARV Therapies and Therapeutic Strategies A CME Newsletter
EACS 2009 11-14, November 2009 Cologne, Germany Course Director Jürgen K. Rockstroh, MD Co-Chairman, 12th European AIDS Conference Professor, University of Bonn Bonn, Germany Faculty Calvin Cohen, MD,
More informationPHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS
8. PHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS David Burger José Moltó Table 8.1a: INFLUENCE OF FOOD ON ABSORPTION (AREA UNDER THE CURVE) OF ANTIRETROVIRAL AGENTS NUCLEOSIDE ANALOGUES NtRTI
More informationOverview of HIV. LTC Paige Waterman
Overview of HIV LTC Paige Waterman Outline Background and Epidemiology HIV Virology, Transmission, and Pathogenesis Acute HIV infection HIV Diagnostics Management of Health Care Personnel Exposed to HIV
More informationHIV Overview. Mary Marovich, MD, DTMH Division of Retrovirology Walter Reed Army Ins?tute of Research US Military HIV Research Program
HIV Overview Mary Marovich, MD, DTMH Division of Retrovirology Walter Reed Army Ins?tute of Research US Military HIV Research Program www.hivresearch.org 1 Outline HIV Virology, Transmission, and Pathogenesis
More informationAntiretroviral Therapy: Panel Discussion
disclosures Antiretroviral Therapy: Panel Discussion Medical Management of HIV December 9, 217 Panelists: Harry Lampiris, MD; Annie Luetkemeyer, MD; Carina Marquez, MD Moderator: Oliver Bacon, MD none
More informationANTIRETROVIRAL TREATMENTS (Part 1of
CCR5 CO-RECEPTOR ANTAGONISTS maraviroc (MVC) Selzentry 25mg, 75mg, FUSION INHIBITORS 20mg/mL ANTIRETROVIRAL TREATMENTS (Part 1of 5) oral soln enfuvirtide (ENF, T-20) Fuzeon 90mg/mL pwd for SC inj after
More informationVIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects
VIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects IL/DLG/0040/14 June 2014 GSK (Israel) Ltd. Basel 25, Petach Tikva. Tel-03-9297100 Medical information service: il.medinfo@gsk.com
More informationCrafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary?
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Crafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary? Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical
More informationWESTERN CAPE ART GUIDELINES PRESENTATION 2013
WESTERN CAPE ART GUIDELINES PRESENTATION 2013 The WC guidelines are based on SA National ART guidelines dated 24th March 2013 Acknowledgement goes to members of the Adult and Paediatric HAST policy advisory
More informationCase # 1. Case #1 (cont d)
Antiretroviral Therapy Management: Expert Panel Discussion George Beatty Susa Coffey Steve O Brien December 3, 2011 Moderated by Annie Luetkemeyer Case # 1 38 y.o. man, CD4 =350, VL=340K, new to your clinic
More informationSecond-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation
More information